Squarepoint
LTRN icon

Squarepoint’s Lantern Pharma LTRN Stock Holding History

Squarepoint’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.4K Buy
+15,296
New +$36.8K ﹤0.01% 4339

Other funds holding LTRN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Westside Investment Management
Westside Investment Management Santa Monica, California $785M AUM 29.89% 1-Year Est. Return
Davenport & Co
Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Entrust Financial
Entrust Financial Wayne, Pennsylvania $205M AUM 12.8% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Squarepoint's LTRN Position: Q3 2026 in Review

Squarepoint opened a new position in Lantern Pharma (LTRN) in Q3 2026: 15,296 shares worth $15.4K. The stake represents ﹤0.01% of the portfolio and ranks #4339 among its holdings.

12 funds tracked by Wall St. Rank hold LTRN as of Q3 2026.

  • Squarepoint held 15,296 shares of Lantern Pharma worth $15.4K as of Q3 2026.
  • Lantern Pharma was a new Squarepoint position in Q3 2026.
  • Lantern Pharma made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4339 holding.
  • 12 funds tracked by Wall St. Rank held Lantern Pharma as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.